Clinical trial to test immune modulation strategy for hospitalized covid-19 patients begins

A clinical trial has launched to test whether early intensive immune modulation for hospitalized COVID-19 patients with relatively mild illness is beneficial. The placebo-controlled study, part of the global clinical trials consortium known as Strategies and Treatments for Respiratory Infections and Viral Emergencies (STRIVE), will enroll approximately 1,500 people at research sites around the world.A clinical trial has launched to test whether early intensive immune modulation for hospitalized COVID-19 patients with relatively mild illness is beneficial. The placebo-controlled study, part of the global clinical trials consortium known as Strategies and Treatments for Respiratory Infections and Viral Emergencies (STRIVE), will enroll approximately 1,500 people at research sites around the world. » The FINANCIAL Health&Beauty

Related Keywords

New Jersey ,United States ,Hugh Auchincloss ,Drug Administration ,National Center ,Translational Sciences ,Bristol Myers Squibb ,Respiratory Infections ,Viral Emergencies ,National Institutes ,National Institute ,Infectious Diseases ,Advancing Translational Sciences ,Director Hugh Auchincloss ,Health Amp Beauty ,